Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Codexis Expands Its Partnership With Arch
September 1, 2008
| A version of this story appeared in
Volume 86, Issue 35
Codexis and Mumbai-based Arch Pharmalabs have expanded an existing three-year supply deal. Under the new agreement, Arch will exclusively manufacture Codexis' active pharmaceutical ingredients (APIs) and intermediates at its 10 facilities in India. Codexis develops routes for making brand-name and generic APIs using biocatalytic processes. Among the products to be manufactured are intermediates used to make generic atorvastatin, the active ingredient in Pfizer's cholesterol-lowering drug Lipitor, as well as the API itself.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X